What ChondroFiller™ does in a hip joint

ChondroFiller™ is an acellular, injectable collagen scaffold — not a lubricant, not a cushioning filler, and not a cell therapy. Manufactured by Meidrix Biomedicals GmbH in Germany, it is a CE-marked Class III medical device composed of murine-derived Type I collagen that gels in place within minutes of entering the joint.

The mechanism is acellular matrix-induced chondrogenesis. Once positioned inside the joint, the scaffold acts as a chemotactic framework: it draws the patient's own progenitor cells — from the surrounding synovium and underlying subchondral bone — into the defect site, where they can differentiate and support endogenous repair. ChondroFiller™ contains no living cells of its own; the repair work is carried out by the body's cells migrating into the scaffold structure.

The hip's articular cartilage, which lines both the femoral head and the acetabulum, is avascular hyaline tissue — it carries no blood vessels and no intrinsic repair capacity. A focal defect in the hip therefore faces exactly the same biological barrier as one in any other joint, which is the structural problem this scaffold is designed to address.

Within the Lincolnshire Hip service pathway, ChondroFiller™ is delivered as an ultrasound-guided outpatient injection under image guidance — no general anaesthetic, no theatre admission.

The hip-specific evidence: what has actually been published

The headline outcome figure from the published hip literature is a Harris Hip Score improvement of +33 points — reported by Mazek et al. in the Journal of Hip Preservation Surgery (2021) at follow-up of 1.5–2 years. With 20 citations to date, this remains the primary outcomes reference for ChondroFiller® in the hip, and the gain places the clinical result in the same territory as other active hip preservation interventions.

A companion contribution from Perez-Carro et al. (PMC, 2021) addresses delivery rather than outcomes. The hip's deep ball-and-socket geometry makes arthroscopic access to the chondral surface considerably more demanding than in the knee, and the authors describe a bespoke curette-and-needle technique developed to overcome this — one that prepares the lesion bed and seats the scaffold precisely enough to avoid displacement of the material into the surrounding joint space. The distinction from a standard needle approach matters: without adequate preparation of the surface, scaffold retention within a focal hip defect cannot be assumed.

The clinical setting for both papers is cam-type femoroacetabular impingement (FAI): an anatomical mismatch at the hip joint that generates focal chondral damage, typically on the anterosuperior acetabulum, in younger and more physically active patients. Left unaddressed, these focal ICRS grade III–IV lesions can progress to osteoarthritis.

Together, Perez-Carro et al. and Mazek et al. represent the full peer-reviewed hip evidence base currently available. Both describe small case series with short-to-mid-term follow-up, and no large randomised controlled trial of ChondroFiller® in the hip has been published.

What the knee studies contribute — and where they stop

Four distinct clinical studies, summarised in the manufacturer's April 2025 Clinical Evaluation Report, form the backbone of the published ChondroFiller® evidence. All four are knee studies. Across them, IKDC functional scores improve by approximately 30 points — more than double the Minimal Clinically Important Difference of 16.7 points. The most rigorous of these, Jerosch et al., recorded a mean gain of +32.4 IKDC points that was sustained, and marginally increased, at three-year follow-up, with patients reaching a mean score of 80. Objective MRI data reinforces the functional picture: MOCART scores of 81.6–84.3 confirm that more than 80% of the knee defect is filled and that the repair tissue integrates well with surrounding native cartilage.

What the knee biology legitimately tells us is that a Type I collagen scaffold reliably recruits host progenitor cells, fills focal defects, and produces durable functional gains. Crucially, that mechanism — acellular matrix-induced chondrogenesis — is not joint-specific. The same chemotactic principle applies whether the scaffold is placed in a knee or a hip, which is why the knee data carries genuine biological relevance beyond the joint in which it was collected.

What the knee data cannot tell us is how those outcomes translate once hip joint geometry, load distribution, and the technical demands of hip access enter the equation. Headline figures cited across the wider ChondroFiller® literature — 70–85% meaningful symptom relief and more than 19,000 procedures performed globally — pool knee, ankle, and small-joint cases together. They are cross-joint aggregate numbers, not hip-specific outcomes.

Why hip anatomy and biomechanics change the clinical picture

Load mechanics in the hip differ fundamentally from the knee. The ball-and-socket joint transmits concentrated, multidirectional forces across the femoroacetabular surface through a wide arc of movement — a biomechanical environment that the knee does not replicate. How this affects ChondroFiller® scaffold retention and tissue maturation in the hip over time has not yet been established in the published literature. Weizel et al. (2020) showed that ChondroFiller® liquid exhibits notably pronounced viscous properties relative to natural cartilage and other collagen gels, providing mechanistic support for its use in load-bearing joints — but hip-specific retention data under sustained hip-loading conditions remains to be reported.

Expertise matters in a practical sense too. Although the bespoke arthroscopic delivery technique described by Perez-Carro et al. was designed to overcome the anatomical access challenges covered earlier, the wider implication for patients is straightforward: the skill base for hip arthroscopy is considerably narrower than for knee arthroscopy, and not every centre offering ChondroFiller® for knee cartilage defects will hold equivalent capability for hip-specific cases.

For patients considering options through Lincolnshire Hip, the distinction between two delivery pathways is clinically important and should not be blurred. Arthroscopic implantation — theatre-based, conducted under anaesthesia, requiring surgical preparation of the defect bed — is reserved for focal ICRS grade III/IV lesions meeting strict selection criteria. Ultrasound-guided outpatient injection, which is the current Lincolnshire Hip service pathway, serves a different patient group: those with suitable wear patterns for whom an image-guided, in-clinic scaffold placement is appropriate. These routes address different clinical needs; neither is a variant of the other.

Which hip patients are likely to benefit

Patients most likely to benefit are those with a focal, full-thickness cartilage defect graded ICRS III or IV on the hip's articular surface — typically an anterosuperior acetabular lesion caused by cam-type femoroacetabular impingement. Published criteria describe lesions of roughly 200–450 mm² (under 2.5 cm²) with healthy cartilage at the defect margins, in a hip that has not progressed beyond Tönnis grade 2. Tönnis grading measures the extent of hip osteoarthritis on plain X-ray; grade 2 or lower indicates that meaningful joint space remains and that the hip is structurally suited to preservation rather than replacement. The typical patient is younger and active, has not responded to physiotherapy and load management, and has been investigated to confirm the defect's grade and boundaries.

Certain presentations fall outside the indication. Established hip osteoarthritis — Tönnis grade greater than 2 — widespread cartilage loss, and large cystic subchondral lesions are all associated with poor outcomes. Patients whose overall hip anatomy is incompatible with joint preservation should be counselled towards a different pathway entirely.

ChondroFiller® is CE-marked but is not NHS-funded and is not covered by most major UK private medical insurers, including Bupa and AXA; confirming funding arrangements before planning treatment is a practical early step.

Confirming suitability requires a thorough assessment, including MRI of the hip joint and standing weight-bearing imaging, to establish defect grade, lesion size, and whether the surrounding cartilage and subchondral bone meet the selection criteria.

How ChondroFiller™ compares with other hip cartilage approaches

Placing ChondroFiller™ alongside the two surgical alternatives most commonly discussed for focal hip cartilage defects clarifies where it sits on the treatment pathway.

Against microfracture. Microfracture perforates the subchondral bone to recruit marrow cells into the defect, producing fibrocartilage rather than hyaline-like repair tissue. Clinical benefit tends to be variable beyond two to three years in hip lesions, and the bone perforation itself is irreversible. ChondroFiller™ avoids subchondral disruption entirely and aims to support hyaline-like tissue formation through acellular matrix-induced chondrogenesis — a structural distinction with potential long-term relevance, though hip-specific head-to-head data does not yet exist.

Against ACI and MACI. Autologous chondrocyte implantation requires two surgical episodes: a cell-harvest arthroscopy followed weeks later by implantation after laboratory culture. The published complication rate for ACI reaches up to 17%, with reoperation rates reported as high as 37%. ChondroFiller™ is a single-stage procedure; the manufacturer's Clinical Evaluation Report records a complication rate of approximately 0% and a reoperation rate of 3–8% across studied cases. These figures derive predominantly from knee populations, and that caveat — consistent with the article's broader theme — applies here too.

ChondroFiller™ is a resorbable regenerative scaffold, not a hydrogel or viscosupplement; conflating it with filler-type therapies would misrepresent the mechanism and misalign patient expectations. Where no large hip RCT yet exists to settle these comparisons definitively, the available case-series evidence is at least internally consistent in favouring its safety profile.